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Summary Incidence and mortality of human malignant melanoma has risen rapidly over recent decades.
Although the notorious resistance to treatment is characteristic for metastatic malignant melanoma, only a few
experimental models have been established to study the metastatic cascade or to test new alternative treatment
modalities. Thus, new human models are wanted. Here, we describe the metastatic behaviour of seven human
melanoma cell lines derived from two primary cutaneous melanomas (WM 98-1, WM 1341) and five metastases
established from liver (UKRV-Mel-4), skin (M7, M13), pleural effusion (UKRV-Mel-2) and lymph node
(MV3). All cell lines were analysed for their capacity to grow in nude mice after s.c. and i.v. administration.
M13 cells developed liver metastases spontaneously after s.c. injection, and subsequent passages of M13 and
M7 melanoma cells caused liver metastases after i.v. injection, whereas MV3 and WM98-1 gave rise to lung
metastases, using the same inoculation route. In contrast, WM 1341, UKRV-Mel-2 and UKRV-Mel-4 grew
only very slowly in nude mice after s.c. injection and did not cause any metastases after i.v. or s.c.
administration. The pattern of metastases or growth kinetics did not correlate with the interleukin 8 or tumour
necrosis factor secretion of cell lines. Adhesion molecules and growth factor receptor expression on the cell
lines differed widely, as determined by flow cytometry, with the low metastatic cell lines (UKRV-Mel-2,
UKRV-Mel-4 and WM 1341) demonstrating a marked reduction in VLA-1 and VLA-5 expression compared
with the metastatic lines (M7, M13, MV3 and WM 98-1). Expression of pigment-related proteins such as
tyrosinase, TRP-1, TRP-2, Melan-A/MART-1, gplOO, MAGEI or MAGE-3 was not associated with growth
and metastatic characteristics of the melanoma cell lines analysed. In conclusion, the established human
melanoma cell lines exhibited diverse growth behaviour in nude mice in congruence with some early established
prognostic markers such as VLA-1 and VLA-5. The xenografts provide good models for further study of
metastatic processes as well as for evaluation ofalternative treatment modalities including new pharmaceutical
drugs and gene therapeutic targeting using tissue-specific gene regulatory elements for gene targeting.
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Human melanoma in its advanced stage is characterised by
frequent metastases to soft tissues such as skin, lung, lymph
nodes and liver, with currently no hope for cure, as
conventional therapeutic strategies are not effective (Ah-
mann et al., 1989). Research on tumour progression,
development of metastases and new therapeutic approaches
such as new drugs or the use of tissue-specific promoter
elements for gene targeting may open up alternative strategies
for the treatment of metastatic melanoma. However, research
is hampered by the lack of well-characterised models.
In order to mimic the human situation as closely as
possible, transplants of human tumours in nude mice are
increasingly used for the investigation of the metastatic
process and the development of new therapeutic modalities
(Fidler, 1986). Various human melanoma cell lines have been
shown to grow in nude mice after s.c. inoculation or to cause
organ metastases after i.v. administration (Fodstad et al.,
1988; van Muijen et al., 1991; Shoemaker et al., 1991; Welch
et al., 1991). However, only a few human melanoma cell lines
give rise to spontaneous metastases in nude mice after s.c.
implantation (Welch et al., 1991; Shoemaker et al., 1991; van
Muijen et al., 1991; Rauth et al., 1994).
We report here the characteristics of seven human
melanoma cell lines established from two primary cutaneous
melanomas and five metastases derived from different tissues
(liver, lymph node, skin and pleural effusion). Growth
behaviour and metastatic capacity in nude mice were
assessed after s.c. inoculation and after i.v. administration.
Furthermore, melanoma cell lines were extensively charac-
terised regarding several adhesion molecules, HLA molecules,
pigment-associated proteins as well as the secretion of
cytokines interleukin 8 (IL-8) and tumour necrosis factor
(TNF-a), which have been shown to be correlated with
metastatic capacity in nude mice (Singh et al., 1994).
Materials and methods
Cell culture
Human melanoma cell lines WM 98-1 and WM1341 were
derived from primary melanomas (Herlyn et al., 1985;
Herlyn, 1990; Lu and Kerbel, 1993) and were kindly
provided by Dr M Herlyn (Wistar Institute, USA). MV3
human melanoma cells were established from a metastatic
melanoma lymph node (van Muijen et al., 1991) and were
kindly provided by Dr van Muijen (Nijmegen, The Nether-
lands). M7 and M13 are newly established human melanoma
cell lines derived from cutaneous metastases. UKRV-Mel-2
(derived from metastatic pleural effusion) and UKRV-Mel-4
(established from a liver metastasis of an ocular melanoma)
were recently described by our group (Artuc et al., 1995).
Details regarding tumour and patient characteristics are given
in Table I. All cell lines were maintained and cultured in
RPMI-1640 medium supplemented with 10% fetal calf serum
(FCS) and antibiotics as described previously (Schadendorf et
al., 1993a).
Correspondence: D Schadendorf, Virchow Clinic, HU Berlin,
Department of Dermatology, Augustenburger Platz 1, 13344 Berlin,
Germany
Received 4 December 1995; revised 14 February 1996; accepted 20
February 1996Melanoma metastases and nude mice
D Schadendorf et al %
195
Polymerase chain reaction (PCR)
PCR was carried out with reversely transcribed cDNA
generated from all melanoma cell lines as described
previously (Schadendorf et al., 1993a). Primer sequences
were devised according to the published sequence for human
tyrosinase (Smith et al., 1991), for MAGE-1 (Van der Bruggen
et al., 1991), for MAGE-3 (Gaugler et al., 1994), for TRP-1
(Shibata et al., 1992), for TRP-2 (Bouchard et al., 1994), for
gplOO (Kwon et al., 1991; Wagner et al., 1995) and for
MELAN-A/MART-1 (Coulie et al., 1994; Kawakami et al.,
1994). The following primers were used: Tyr-l: TTG GCA
GAT TGT CTG TAG CC and Tyr-2: AGG CAT TGT GCA
TGC TGC TT, which generate a 284 bp DNA amplificate
specific for tyrosinase; Tyr-3: GTC TTT ATG CAA TGG
AAC GC and Tyr-4: GCT ATC CCA GTA AGT GGA CT
generate a second 207 bp DNA amplificate specific for
tyrosinase; MAGE1-5: TTG CCG AAG ATC TCA GGA A
and MAGE1-3: CTT GCC TCC TCA CAG AG generate a
470 bp DNA amplificate specific for the MAGE-J gene;
MAGE3-5: TGG AGG ACC AGA GGC CCC C and
MAGE3-3: GGA CGA TTA TCA GGA GGC CTG C
generate a 714 bp DNA amplificate specific for the MAGE-3
gene; TRP-15: AAA GGA TTA GTA AAG GGT and TRP-
13: CAT TCT GCT TGA AAT AAG generate a 670 bp DNA
amplificate specific for the TRP-J gene; TRP-25: CTG GGT
GCA GAG TCG GCC and TRP-23: ATT GGG CCC AAG
CAG GCC generate a 300 bp DNA amplificate specific for the
TRP-2 gene; pMEl175: AGA TCC TGC AGG CTG TGC
and pMell73: CAA TGG GAC AAG AGC AGA generate a
540 bp DNA amplificate specific for the gpJOO/pMell7 gene;
MART1-5: ACT GCT CAT CGG CTG TTG and MART1-3:
TCA GCC ATG TCT CAG GTG generate a 265 bp DNA
amplificate specific for the MART-I/MELAN-A gene.
Flow cytometric analysis
Cell staining was performed using mouse monoclonal
antibodies, followed by FITC-conjugated, affinity purified,
isotype-specific goat anti-mouse antibodies (Immunotech,
Hamburg, Germany) as described previously (Bohm et al.,
1994). The samples were analysed on a Coulter Epics XL
Flow Cytometry System (Miami, FL, USA). The following
MAbs were used: B9.12.1 (IgG2a, anti-HLA-A,B,C, Immu-
notech, Hamburg, Germany), B.9.12.2 (IgG2b, anti-HLA-DR,
Immunotech), 84H10 [IgGj, anti-ICAM-1 (CD54)], 225.28
(IgG, anti-HMW-MAA, gift from Dr S Ferrone; Hamby et
al., 1987), 376.96 (IgG, anti-100 kd-MAA, gift from Dr S
Ferrone; Hamby et al., 1987), ENA-1 [IgG, anti-ELAM-1
(CD62E), Dianova, Hamburg, Germany], GRO-1 (IgG1,
anti-EGF-R, Dianova), YDJ 1.2.2. [IgG1, anti-Tansferrin-R
(CD71), Dianova], ROS 220 (IgG1, anti-CD44s, Dianova),
TS2/7 (IgGj, anti-CDw49a, VLA-1, T Cell Science), Gi9
(IgG1, anti-CDw49b, VLA-2, Dianova), PiB5 (IgGj, anti-
CDw49c, Gibco), HP2/1 (IgG1, anti-CDw49d, Dianova),
SAM-I (IgG2a, anti-CDw49e, Dianova), GoH3 (IgG2a, anti-
CDw49f, Dianova), AMF/7 (IgG1, anti-CD51, Dianova),
SZ21 [IgG,,anti-CD61 (fl3), Dianova]. All samples were
analysed using propidium iodide to exclude dead cells.
Melanogenic activity assays
Melanogenic activity of the seven different cell lines was
measured by enzymatic assays using ['4C]tyrosine for melanin
formation and [3H]tyrosine for tyrosine hydroxylase activity
as described previously (Artuc et al., 1995). The tyrosine
hydroxylase assay measures only the first enzymatic function
of the tyrosinase. The melanin formation assay measures the
complete reaction sequence and reflects the melanogenic
activities of tyrosinase, TRP-1 and TRP-2 (Hearing and
Tsukamoto, 1991). Briefly, cells were harvested with trypsin-
EDTA, solubilised with 100 pl of 1% NP-40 in 0.05 M Tris-
HCl, pH 7.2, for 60 min at 4°C, and centrifuged for 15 min
at 15 000 r.p.m.
Tyrosine hydroxylase assay
Tyrosine hydroxylase activity was measured by monitoring
conversion of L-[3H]tyrosine to L-dopa and the production of
3H20 as described (Artuc et al., 1995). Cell extracts (50 ig of
protein) were incubated in 50 ,ul of a reaction mixture
containing 0.25 mM L-tyrosine, 5 ,iCi ml-1 [3H]tyrosine and
0.05 mM L-dopa in 0.1 M phosphate buffer (pH 6.8) for 2 h
at 37°C. The reaction was terminated by addition of0.4 ml of
charcoal (Norit SG activated charcoal) [10% (w/v) in 1%
trichloroacetic acid (TCA)] and counted for radioactivity in a
#-counter. One unit of the tyrosine hydroxylase was defined
as the amount of the enzyme that catalyses the hydroxylation
of 1 ,umol L-tyrosine min-'.
Melanin formation assay
Aliquots (30 1l) of the extracts were used to measure melanin
formation as described previously (Artuc et al., 1995).
Incubations were performed at 37°C in a final volume of 50 jul
for 2 h as for tyrosine hydroxylase (same substrate and final
concentrations ofthe same co-factors), with ['4C]tyrosine as the
radioactive substrate at a concentration of0.106 mM (sp. act.:
50 Ci mmol-1). The reaction was stopped by the addition of
150 p1 ofa solution containing 6% TCA and 10 mM unlabelled
tyrosine. The sampleswerepassedthroughfibreglassfilters, and
the filters were washed three times with 3 ml of 0.1 M
hydrochloric acid, dried and counted in a fl-counter.
Melanin content
Melanin content of the cells was calculated from the
absorption of the cellular extracts compared with a standard
curve for synthetic melanin at 475 nm (Artuc et al., 1995). To
measure the extent of melanisation, cell extracts containing
200 Mg of protein were heated at 90°C for 2 h in 1 ml of
0.1 N sodium hydroxide and centrifuged at 14 000 r.p.m. for
20 min. The optical density of the supernatant was then
measured at 475 nm.
Cytokine secretion
For the determination of IL-8 and TNF-c, secretion,
melanoma cells were maintained as described above. Cells
were grown to subconfluence, washed twice with phosphate-
buffered saline (PBS) and incubated with RPMI-1640 without
FCS in two parallel sets with and without phorbol-
myristate-acetate (1 ng ml-') for 16 h at 37°C. Thereafter,
aliquots of the cell-free supernatant were collected and
analysed for their content of IL-8 and TNF-oa protein by
specific ELISA. Secreted IL-8 protein was measured using a
sandwich ELISA employing two specific monoclonal anti-
bodies as recently described (Sticherling et al., 1989) and
TNF-a protein was determined using a commercially
available ELISA (R&D Systems, Bad Nauheim, Germany).
Animals
For the in vivo experiments, male NMR/I: nu/nu mice
(Bomholtgaard, Ry, Denmark) weighing 20-25 g were used.
Mice were held under sterile conditions at 24-26°C room
temperature, 50% relative humidity and 12 h light-dark
rhythm in laminar flow shelves receiving autoclaved food
(Sniff, Soest, Germany) and bedding. The drinking water was
filtered and acidified (pH 4.0).
In vivo transplantation
For transplantation, melanoma cells were harvested by
trypsinisation (0.25% trypsin; Seromed, Berlin, Germany)
from cell culture flasks and were washed twice with PBS.
Subsequently, cells were injected either s.c. (107 cells per
mouse) into the right flank or i.v. (106 cells per mouse) into
the tail vein of 2-3 animals each).Melanoma metastases and nude mice
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Mice were visited daily, and growing tumours were
measured twice weekly with a caliper-like instrument.
Moribund mice or mice whose tumours reached a diameter
of 15 mm were killed by cervical dislocation. Non-necrotic
tissues of primary tumours or metastases were cut into pieces
of 2-3 mm diameter and used for further s.c. passages (P1,
P2). In some cases, tumours were mechanically disaggregated
with a glass homogeniser, and the resulting cell suspension
was injected i.v. (106 cells per mouse). Metastases were
semiquantitatively evaluated in all organs as follows: +,
single small metastatic nodules; + +, up to five metastatic
nodules of 4-5 mm diameter; + + +, numerous nodules/
massive metastatic infiltration.
Results
Growth and metastatic capacity in nude mice
All seven human melanoma cell lines were administered s.c.
(107 cells per mouse) and i.v. (106 cells per mouse). The time
interval between s.c. injection and tumour development
ranged between 8 and 86 days. The growth of melanoma
metastases after i.v. administration took between 42 and 120
days (Table II). Three cell lines (Ml3, UKRV-Mel-4, WM
1341) did not generate any metastases after i.v. injection and
UKRV-Mel-2 gave rise to a lymph node metastasis in one of
three mice without success of further passing the tumour cells
to further animals. In addition, those melanoma cell lines
with no or low metastatic capacity after i.v. injection, such as
M13, UKRV-Mel-4, WM 1341 and UKRV-Mel-2 grew into
small cutaneous tumours only after s.c. administration. In
contrast, WM 98.1 and MV3 reproducibly generated
numerous lung metastases 120 and 55 days, respectively,
after i.v. inoculation. M7 cells as well as M13 cells derived
from a mouse liver metastasis (Ml 3p2,iver) also led repeatedly
to liver metastases after i.v. injection (Table II). Furthermore,
M7, WM 98.1 and MV3 melanoma cells, which all
demonstrated some metastatic capacity after i.v. administra-
tion, formed, in addition, massive cutaneous tumours upon
s.c. application. However, in all cases, no spontaneous
systemic metastases were detected. Only M13 melanoma
cells originally derived from a cutaneous melanoma
metastasis produced not only large cutaneous tumours, but
also spontaneously induced liver metastases (Table II).
Passage of these cells into further animals led to a subclone
(M13P2liver), which demonstrated a high capacity to generate
repeatedly liver metastases independent of inoculation route
(s.c. or i.v.) with a latency period of around 65 days.
Secretion of IL-8 and TNF-cx
As cytokines, particularly IL-8, have been thought to
influence the proliferation of human melanoma cells in vitro
(Schadendorf et al., 1993a) and to alter the metastatic and
growth behaviour in nude mice (Singh et al., 1994), we
analysed the expression of IL-8 and TNF-cx on RNA level by
reverse transcriptase-polymerase chain reaction (RT-PCR)
and on protein level by ELISA. IL-8 protein levels ranged
between 0 and 25 ng ml-' per 100 000 cells 16 h-'
independent of stimulation with phorbol 12-myristate 13-
acetate (PMA) (Table III). Similarly, TNF-a was detectable
in two of six (unstimulated) and in three of six (PMA-treated)
cell lines, with protein levels between 0 and 170 ng ml-' per
100 000 cells 16 h-'. IL-8 and TNF-oa secretion levels in vitro
were not associated with origin of tumour and with the
capacity to grow or metastasise in nude mice.
Table I Origin of melanoma cell lines established on nude mice
Melanoma cell line Source ofmetastasis Gender Tumour type Tumour thickness Localisation of PT Reference
M7 Cutaneous Male NM 5.00mm Neck Unpublished
M13 Cutaneous Female NM 7.0mm Arm Unpublished
UKRV-MEL-4 Liver Female Ocular Eye Artuc et al. (1995)
UKRV-MEL-2 Pleural effusion Female SSM 1.8mm Arm Artuc et al. (1995)
WM 98-1 Primary melanoma ? SSM ? ? Herlyn et al. (1985)
WM 1341 Primary melanoma ? SSM ? ? Herlyn (1990)
MV3 Lymph node Male NM 60mm Chin van Muijen et al.
(1991)
PT, primary tumour.
Table II Establishment of human melanoma cell lines on nude mice. Determination of tumour take, tumour growth after s.c. inoculation (107
cells per mouse) and development of metastases after s.c. or i.v. injection of melanoma cells (106 cells)
Melanoma Number of mice Latency in days
cell line Inoculation site (n) Primary tumour Metastases Description of tumour take and metastases
M7 s.c. 3 34 3/3 massive cutaneous tumours; no metastases
i.v. 3 100 1/3 liver metastases + +; ascites
M13 s.c. 3 34 42 1/3 liver metastases + +; ascites
i.v. 3 90+ Mice alive, no metastases
M13 P2 liver s.c. 2 30 71 2/2 liver metastases + +
i.v. 2 64 1/2 liver metastases +
UKRV-MEL-4 s.c. 3 22 2/2 small cutaneous tumours, mice alive, no metastases
i.v. 3 100+ Mice alive, no metastases
UKRV-MEL-2 s.c. 3 8 3/3 cutaneous tumors; mice alive; no metastases
i.v. 3 85 1/3 lymph node metastases +
WM 98-1 s.c. 3 39 3/3 cutaneous tumors; no metastases
i.v. 3 120 3/3 lung metastases + + + +
WM 1341 s.c. 3 86 2/2 small cutaneous tumours, no metastases
i.v. 3 150+ Mice alive, no metastases
MV 3 s.c. 3 22 Massive cutaneous tumors-no metastases
i.v. 3 55-85 3/3 lung metastases + + + +
MV P2 lung i.v. 3 54 3/3 lung metastases + + + +Phenotypic analysis byflow cytometry
As adhesion molecules have been shown to be critically
involved in the metastatic process (Liotta and Stetler-
Stevenson, 1991), an extensive phenotypic flow cytometric
analysis was performed including the integrins VLA-l toVLA-
6, CD51 and CD61. Furthermore, additional adhesion
molecules such as CD44, ICAM-1 and ELAM-1 were studied
as well as HLA class I and HLA-DR expression. Cell-surface
expression differed widely (Table IV), without obvious
association of expression pattern and growth kinetics or
metastatic capacity in nude mice, except for a marked
reduction in expression levels of VLA-1 and VLA-5 in the
low metastatic melanoma cell lines UKRV-Mel-2, UKRV-
Mel-4 and WM1341. Furthermore, melanoma cell line UKRV-
Mel-2 exhibited a complete loss of HLA class I expression
without any effect on its biological behaviour in vivo.
Expression ofpigmentation-associated proteins
The expression of a number of pigmentation-associated
proteins (Hearing and Takamoto, 1992), such as tyrosinase,
TRP-1, TRP-2, Melan A/MART-1, gplOO, MAGE-1 and
MAGE-3, which have recently been described to be
Table III Secretion of interleukin 8 (IL-8) and tumour necrosis
factor (TNF-a) unstimulated fUS) and upon stimulation with PMA
(Ingml-') (10 melanoma cells, 16h)
IL-8 protein (ngmt') TNF-a protein (ngmrl)
Melanoma cell line US PMA US PMA
M7 1.6 1.6 25 25
M13 0 0 0 0
UKRV-MEL-4 0 0 0 170
UKRV-MEL-2 25 25 0 0
WM 98-1 1.8 1.3 40 40
WM 1341 0.4 0.4 0 0
MV3 ND ND ND ND
ND. not done.
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recognised as peptides by cytolytic T lymphocytes in
conjunction with HLA class I molecules (Houghton, 1994),
were assessed by RT-PCR, as shown in Table V. Three of
seven melanoma cell lines expressed tyrosinase mRNA, four
of seven expressed gplOO, and two of seven exhibited TRP-2
and MELAN-A gene expression at the RNA level whereas
TRP-1 was not detectable in any cell line. Similarly, MAGE-3
could not be amplified in any melanoma cell line whereas
MAGE-1 was present in three of seven cell lines (Table V).
Furthermore, the enzymatic activities of tyrosinase and
tyrosine hydroxylase as well as the melanin content were
measured in the amelanotic melanoma cell lines. No
tryosinase activity or melanin was detectable in any cell line.
Low tyrosine hydroxylase activity was measured in UKRV-
Mel-2 and WM 98-1 cells, which both showed expression ofat
least two pigmentation-associated proteins by RT-PCR (Table
V). However, expression patterns analysed by RT-PCR or
biochemically differed widely without any correlation with the
biological behaviour of the melanoma cell lines in vivo.
Discussion
As the prognosis of patients suffering from metastatic
melanoma is poor despite conventional therapies (Ahmann
et al., 1989), model systems close to the human situation are
needed to develop new therapeutic strategies including drug
screening or gene delivery systems (Miller and Vile, 1995). In
the present study, we analysed seven human melanoma cell
lines for their growth behaviour in nude mice. The pattern of
metastatic spread differed between cell lines with M7 and
M13 leading to liver metastases, UKRV-Mel-2 to lymph
node metastasis and MV3 and WM98-1 to lung metastases
after i.v. injection. All these organs are frequent locations of
melanoma metastases in humans. However, no relation was
found between origin of the original tumour and organ
specificity of metastases in nude mice. For instance, UKRV-
Mel-4, which originated from a liver metastasis of an ocular
melanoma, totally lacked metastatic potential in nude mice
Table IV Phenotypic characterisation of melanoma cell lines by flow cytometric analysis
M7 M13 UKRV-MEL-4 UKRV-MEL-2 WM 98-1 WM 1341 MV3
(%) (%) (%) (%) (%) (%) (%)
VLA-1 (CD49a) 77 (+) 88 + - 16 (+) 17 (+) 98 + 16 (+) 60 (+)
VLA-2 (CD49b) 56 (+) 54 (+) 95 + 40 (+) 96 + 17 95 +
VLA-3 (CD49c) 100 ++ 90 + + 98 ++ 69(+) 98 + + 99 + + 96 ++
VLA-4 (CD49d) 93 + 88 + 0 90 + 42 (+) 69 (+) 92 +
VLA-5 (CD49e) 100 + 88 + 21 (+) 0 90 + 9(+) 63(+)
VLA-6 (CD49f) 70 (+) 48 (+) 98 + + 27 (+) 88 + 4 (+) 63 (+)
VNR (CD51) 97 + 91 + 97+ 94 + 98 ++ 73 (+) 93 +
ICAM-1 (CD54) 76 (+) 78 + 16 (+) 100 + + 100 ++ 96 + + 98 + +
ELAM-1 (CD62E) 0 0 7 (+) 0 0 0 0
CD61 7 (+) 31(+) 0 75(+) 90 + 11(+) 0
TFR (CD71) 43 (+) 62 (+) 67 (+) 63 (+) 79 + 20 (+) 32 (+)
CD44 100 (+ +) 88 + + 97 ++ 1l0 + + 98 ++ lO0 + + 97 + +
EGF-R 50 (+) 41(+) 97 ++ 4(+) 57 (+) 0 40 (+)
HLA-class I 100 ++ 90 ++ 100 ++ 0 100 ++ 100 ++ 98 + +
HLA-DR 0 0 0 16 + 82 + 100 ++ 0
HMW-MAA 30 (+) 5 (+) 0 65 (+) 0 18 (+) 19 (+)
MAA 95 + 81 + 92 + 67(+) 53(+) 39(+) 0
Percentage ofpositively stained cells are given. Intensity ofstaining was semiquantified: (+), dim staining; +, medium intensity staining; + +,
bright staining.
Table V Characterisation of human melanoma cells regarding melanogenesis-related enzymes, melanin formation and mRNA expression of
proteins detected by anti-tumour cytolytic T-lymphocytes (Houghton, 1994)
mRNA expression Enzyme activities
Melanoma MELAN-A/ Melanin Tyrosine
cell line Tyrosinase TRP-1 TRP-2 gp 100 MART-I MAGE-J MAGE-3 Tyrosinase content hydroxylase
M7 - - - - - ND ND ND
M13 - - + - ND ND ND
UKRV-MEL-4 - +
UKRV-MEL-2 + + + + - +
WM 98-1 + + + +
WM 1341 + + + + +
MV3
ND, not done..sI- m.tt md duf - e* D Schadndorf et i
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whereas MV3 cells derived from a metastatic lymph node
spread exclusively to lung. These observations are in
agreement with findings of Rodolfo et al. (1988) who
described the same heterogeneity of origin of tumour cell
line and metastatic profile in nude mice.
In the literature, several procedures such as orthotopic
transplantation (Juhasz et al., 1993; Hoffmann et al., 1994),
the use of severe combined immunodeficient (SCID) instead
ofnude mice (Xie et al., 1992; Taglian and Huang, 1995) and
the mixture of tumour cells in matrigel (Bonfil et al., 1994;
Metha et al., 1995) have been recommended in order to
increase the frequency of metastases in human xenograft
systems. Apparently, such techniques are possibly not as
crucial in human melanomas as in other tumour systems, as
in this study, five of seven melanoma cell lines gave rise to
metastases upon i.v. or s.c. inoculation. One (M13) of the
seven melanoma lines described here spontaneously devel-
oped liver metastases, a rare metastatic pattern of human
melanoma in nude mice after s.c. transplantation. In general,
spontaneously metastasising tumour cell lines in nude mice
are rare (-2%), as recently reviewed by Taglian and Huang
(1995). Only a few have been described, including LOX
amelanotic melanoma cells, which metastasise frequently to
the lung (Shoemaker et al., 1991), C8161 melanoma cells
leading to lung, lymph node, spleen and skin metastases
(Welch et al., 1991) and UISO-Mel-6 (lung and liver
metastases; Rauth et al., 1994). Furthermore, MV-3
melanoma cells have been described to spontaneously
metastasise to lung upon s.c. transplantation (Van Muijen
et al., 1991), which did not happen in our case (Table H).
However, in agreement with van Muijen et al., MV3 cells
produced large numbers of lung metastases after i.v.
injection. One possible explanation for this discrepancy
might be a partial change in marker expression at the cell
surface such as that of the transferrin receptor (CD71) and
the HMW-MAA, which were both dramatically reduced
(32% and 19%) compared with the report by van Muijen et
al. (80-100% and 70-100% respectively). The expression of
HLA molecules and VLA-2 was not altered (Table IV; van
Muijen et al., 1991).
The exact mechanism involved in the different patterns of
metastasisation after s.c. transplantation of the cell lines in
nude mice are unknown. The expression ofvarious oncogenes
(Welch et al., 1991; Rauth et al., 1994), of glucoconjugates,
CD44 (van Muijen et al., 1995) and integrins (van Muijen et
al., 1991; Danen et al., 1995) have been found to be
associated with differential biological behaviour in the past.
In the present analysis, CD44 expression was not altered in
comparing low metastatic melanoma cell lines (UKRV-Mel-2,
UKRV-Mel-4 and WM1341) with more aggressive M7, M13
and MV3 cells. However, integrins VLA-1 and VLA-5 were
dramatically unregulated in the aggressive, highly metastatic
cell lines, which parallels immunohistological results on
melanocytic tumours studying integrin expression during
tumour progression. In those reports, VLA-1, a receptor
for collagen and laminin, and VLA-5, a receptor for
fibronectin, (Ruoslahti, 1991) were found to be u-regulated
during malignant transformation and progression of melano-
cytic cells (Moratini et al., 1992; Schadendorf et al., 1993b;
Danen et al., 1994). Interestingly, UKRV-Mel-2, which
completely lacked any HLA-class I molecule expression on
its cell surface was characterised by a poor growth rate in
nude mice without development of metastases, independent
of inoculation route. UKRV-MEL-2 is only the third human
melanoma cell line besides FO-1 (D'Urso et al., 1991) and
SK-Mel-33 (Wang et al., 1993) that completely lacks HLA-
class I expression, which is caused in FO-l and SK-Mel-33 by
firmicroglobulin mutations. However, the reason for the
missing expression in UKRV-Mel-2 is presently unknown.
No association was found between metastatic capacity and
IL-8 or TNF secretion, in contrast to a recent report
suggesting a close association between IL-8 secretion and
metastatic potential of i.v. injected human melanoma cells
(Singh et al., 1994). Furthermore, the expression of
melanosomal proteins, often considered to be differentiation
markers (Hearing and Tsukamoto, 1991), and the capacity
for metastasis formation in nude mice were not linked.
Taken together, various human melanoma cell lines have
been established in nude mice and were found to give rise to
systemic metastases after i.v. or s.c. injection. Reasonable
growth rates as well as a well-characterised cell phenotype
including melanosomal proteins make these human xenograft
lines suitable candidates to study the metastatic process and
factors involved in organ-specific metastases patterns.
Furthermore, this model may also be highly valuable for
drug screening and to test targeted vectors for gene therapy,
as recently proposed by Miller and Vile (1995).
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